Zydus Receives Tentative Approval From The USFDA For Empagliflozin Tablets

Zydus Cadila has received tentative approval from the USFDA to market Empagliflozin Tablets, in the strengths of 10 mg and 25 mg (US RLD: Jardiance® Tablets).

The medication is used together with diet and exercise to improve blood sugar control in adults with Type 2 diabetes mellitus. It is also used to reduce the risk of cardiovascular death in adult patients with Type 2 diabetes mellitus and established cardiovascular disease.

The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group now has 286 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.350.7 as compared to the previous close of Rs. 349.95. The total number of shares traded during the day was 1057727 in over 30547 trades.

The stock hit an intraday high of Rs. 378 and intraday low of 348.2. The net turnover during the day was Rs. 378871200.-Equity Bulls